Furiex Pharmaceuticals (FURX) 75.24 $FURX
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Furiex Pharmaceuticals Announces First Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2014 financial results on Wednesday, May 7, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
Furiex Pharmaceuticals Announces Acceptance to Late-Breaking Abstract Session at Digestive Disease Week 2014
Business Wire - Thu Apr 03, 3:23PM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.
Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data from the EXAMINE Trial at the American College of Cardiology's 63rd Annual Scientific Session
Business Wire - Thu Mar 27, 10:07AM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure (HF).
Trade-Ideas: Furiex Pharmaceuticals (FURX) Is Today's "Dead Cat Bounce" Stock
at The Street - Thu Mar 13, 2:53PM CDT
Trade-Ideas LLC identified Furiex Pharmaceuticals (FURX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Furiex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Tue Mar 11, 3:30PM CDT
--Royalty revenues of $8.1 million, an increase of $2.6 million (47%) from third quarter 2013.
Furiex Pharmaceuticals Confirms Takeda's Submission of a New Drug Application for Trelagliptin Succinate (SYR-472) in Japan for the Treatment of Type 2 Diabetes
Business Wire - Fri Mar 07, 11:21AM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate (SYR-472), a once weekly dosage treatment for type 2 diabetes.
Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company"
(NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes" in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing.
3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
Bull of the Day: Endocyte (ECYT) - Bull of the Day
Kevin Cook - ZACKS - Wed Feb 12, 4:03AM CST
Bull of the Day: Endocyte (ECYT) - Bull of the Day
Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...
Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release and Conference Call
Business Wire - Mon Feb 10, 3:10PM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter 2013 financial results on Tuesday, March 11, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 08, 8:00AM CST
Seattle Seahawks fans are no doubt still celebrating their team's big victory in the Super Bowl last Sunday. But they're not the only ones with reason to be cheerful. Several health-care stocks enjoyed humongous gains this week. Great clinical...
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
3 Stocks Breaking Out on Unusual Volume
at The Street - Thu Feb 06, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Furiex Soars on Positive Eluxadoline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 1:29PM CST
Shares of Furiex more than doubled on Feb 4 to close the trading session at $105.69.
Company news for February 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:06AM CST
Companies in the News are: FURX,MSFT,ATMI,PSTI
Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:04AM CST
Furiex Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by nearly 130% on the day.
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Furiex Pharmaceuticals Announces First Quarter 2014 Earnings Release and Conference Call
Business Wire - Mon Apr 07, 3:15PM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2014 financial results on Wednesday, May 7, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
Furiex Pharmaceuticals Announces Acceptance to Late-Breaking Abstract Session at Digestive Disease Week 2014
Business Wire - Thu Apr 03, 3:23PM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW) 2014, to be held May 3-6 at McCormick Place in Chicago, IL.
Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data from the EXAMINE Trial at the American College of Cardiology's 63rd Annual Scientific Session
Business Wire - Thu Mar 27, 10:07AM CDT
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure (HF).
Trade-Ideas: Furiex Pharmaceuticals (FURX) Is Today's "Dead Cat Bounce" Stock
at The Street - Thu Mar 13, 2:53PM CDT
Trade-Ideas LLC identified Furiex Pharmaceuticals (FURX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Furiex Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results
Business Wire - Tue Mar 11, 3:30PM CDT
--Royalty revenues of $8.1 million, an increase of $2.6 million (47%) from third quarter 2013.
Furiex Pharmaceuticals Confirms Takeda's Submission of a New Drug Application for Trelagliptin Succinate (SYR-472) in Japan for the Treatment of Type 2 Diabetes
Business Wire - Fri Mar 07, 11:21AM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate (SYR-472), a once weekly dosage treatment for type 2 diabetes.
Regal Entertainment Group Announces Proposed Senior Notes Offering
Business Wire - Tue Feb 25, 6:49AM CST
Regal Entertainment Group ("Regal" or the "Company"
(NYSE:RGC) announced today that it plans to offer senior notes due 2022 (the "Notes" in a registered offering. The principal amount, interest rate and certain other terms of the offering will be determined at the time of pricing. 3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
Bull of the Day: Endocyte (ECYT) - Bull of the Day
Kevin Cook - ZACKS - Wed Feb 12, 4:03AM CST
Bull of the Day: Endocyte (ECYT) - Bull of the Day
Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...
Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release and Conference Call
Business Wire - Mon Feb 10, 3:10PM CST
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter 2013 financial results on Tuesday, March 11, 2014, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 08, 8:00AM CST
Seattle Seahawks fans are no doubt still celebrating their team's big victory in the Super Bowl last Sunday. But they're not the only ones with reason to be cheerful. Several health-care stocks enjoyed humongous gains this week. Great clinical...
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
3 Stocks Breaking Out on Unusual Volume
at The Street - Thu Feb 06, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Furiex Soars on Positive Eluxadoline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 1:29PM CST
Shares of Furiex more than doubled on Feb 4 to close the trading session at $105.69.
Company news for February 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:06AM CST
Companies in the News are: FURX,MSFT,ATMI,PSTI
Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:04AM CST
Furiex Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by nearly 130% on the day.
